Volumen: 20 # Number : 2
Publication Date : Mayo - Agosto Year: 2016
Brentuximab vedotin, a new therapeutic alternative in
patients with relapsed or refractory Hodgkin lymphoma:
the argentine experience
Authors: Negri Aranguren F, Prates MV, Burgos R, Shanley, C,
Kusmisnky, G, Fernández I, Otero V, Schutz N, Cranco S,
Pavlovsky MA, Cerutti I, Huber M, Riveros D, Jarchum
G, Remaggi G, García JJ, Mariano R, Miodosky M,
Zárate T, Tamashiro M, Tosin MF, Zerga M, Szelagowski
M, Intile D, Pavlovsky A
Abstract: Brentuximab vedotin (BV) is an
antibody-drug conjugate that selectively delivers
monomethyl auristatin E, an antimicrotubele agent,
into CD30 expressing cells. It proved to be effective
in the treatment of patients with relapsed or refractory
Hodgkin lymphoma (R/R HL) with a suitable
toxicity profile(1).
Patients and methods: Forty nine patients with relapsed
refractory HL and treated with BV, from 17
centers in Argentina were evaluated retrospectively.
The dose of BV was 1.8 mg/kg intravenously once
every 3 weeks, the median number of cycles was 7
(range 2-18).
Results: The OR was 61% (30 patients), 24% (12
patients) achieved CR. The subgroups of patients
which had relapsed after one year had an OR of 90%
compared with 49% in primary refractory patients
or in those who relapsed within the first year (p =
0.0015). The median PFS and median OS for the
whole group were 20 and 29 months respectively.
In patients who achieved CR the median PFS was
55 months. The most common adverse events (AE)
were nausea (35%), infections (32%) and peripheral
sensory neuropathy (32%). Nine patients (18%) experienced
AE grade 3-4.
conclusion: In our experience BV was associated
with manageable toxicity and induced objective responses
in 61% of patients with R/R HL: the subgroup
of patients with relapses after their first year
had better outcome.
Key words: Hodgkin lymphoma
Brentuximab vedotin
Antineoplastic agents
Pages :
|
